Research reveals a higher cancer risk for rheumatoid arthritis patients using certain biologics, emphasizing the need for ...

Further follow-up of an increased number of patients is needed to know how this will impact on long-term treatment of rheumatoid arthritis patients with rituximab.

Further follow-up of an increased number of patients is needed to know how this will impact on long-term treatment of rheumatoid arthritis patients with rituximab.

Patients with rheumatoid arthritis (RA ... suggest that treatment with the B-cell depleting agent, rituximab, lowers the response to certain vaccines, but not to others. Bingham and colleagues ...

Rheumatoid arthritis (RA ... antagonist that is approved for the treatment of RA for use alone or in combination with DMARDs other than TNF inhibitors. Rituximab, a mAb that binds to CD20 on ...

Medicare Part B (medical insurance) may cover Rituxan (rituximab ... Medicare will usually pay 80% of the costs of treatment. The individual will be responsible for the remaining 20%.

Targeted drugs for rheumatoid arthritis (RA ... (Orencia), and the B-cell depletion agent rituximab (Rituxan), the ...